International Clinical Trials in Hematology

Argentina

• Anemia: LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Buenos Aires ; Research Site:
  
  
• Anemia: LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Córdoba; Research Site:
  
  
• Anemia: LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Santa Fe; Research Site:
  
  

Australia

• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Gosford; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Liverpool; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Melbourne; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Parkville; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Sydney; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Woolloongabba; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Gosford; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Liverpool; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Melbourne; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Parkville; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Perth; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Sydney; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Woolloongabba; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Adelaide; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Gosford; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Melbourne; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Parkville; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Woolloongabba; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.
  Adelaide; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.
  Brisbane; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.
  Melbourne; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
  Adelaide; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
  Brisbane; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
  Melbourne; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Liverpool; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Melbourne; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Parkville; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Perth; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.
  Adelaide; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.
  Gosford; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.
  Melbourne; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.
  Parkville; Research Site:
  
  
• Anemia: COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
  Adelaide; Research Site:
  
  
• Anemia: COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
  Gosford; Research Site:
  
  
• Anemia: COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
  Liverpool; Research Site:
  
  
• Anemia: COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
  Melbourne; Research Site:
  
  
• Anemia: COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
  Parkville; Research Site:
  
  
• Anemia: COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
  St. Leonards; Research Site:
  
  
• Anemia: COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
  Sydney; Research Site:
  
  
• Anemia: COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
  Woolloongabba; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Adelaide; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Frankston; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Gosford; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Malvern; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Melbourne; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Parkville; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Randwick; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Sydney; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Westmead; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Woolloongabba; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Adelaide; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Frankston; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Fremantle; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Melbourne; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Woolloongabba; Research Site:
  
  

Austria

• Anemia: (ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy
  Linz; Research Site:
  
  
• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  Bludesch; Research Site:
  
  
• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  Graz; Research Site:
  
  
• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  Wien; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Graz; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Graz; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Linz; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Wien; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
  Linz; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
  Salzburg; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
  Wien; Research Site:
  
  
• Anemia: A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
  Linz; Research Site:
  
  
• Anemia: A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
  St Pölten; Research Site:
  
  
• Anemia: MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.
  Baden; Research Site:
  
  
• Anemia: MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.
  Feldkirch; Research Site:
  
  
• Anemia: MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.
  Graz; Research Site:
  
  
• Anemia: MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.
  Kufstein; Research Site:
  
  
• Anemia: MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.
  Linz; Research Site:
  
  
• Anemia: MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.
  Salzburg; Research Site:
  
  
• Anemia: MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.
  St Pölten; Research Site:
  
  
• Anemia: MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.
  Steyr; Research Site:
  
  
• Anemia: MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.
  Wien; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Graz; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Salzburg; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Wien; Research Site:
  
  
• Multiple Myelomas: A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma
  Salzburg; Research Site:
  
  
• Multiple Myelomas: A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma
  Wien; Research Site:
  
  

Belgium

• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  Aalst; Research Site:
  
  
• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  Leuven; Research Site:
  
  
• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  Namur; Research Site:
  
  
• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  Wilrijk; Research Site:
  
  
• Anemia: (MARCH Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Advanced Cervical Cancer
  Leuven; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Aalst; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Bruxelles; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Liege; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Aalst; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Bruxelles; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Edegem; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Gent; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Hasselt; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Leuven; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Liege; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Aalst; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Bruxelles; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Roeselare; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.
  Antwerpen; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.
  Liege; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
  Aalst; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
  Edegem; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
  Liege; Research Site:
  
  
• Anemia: A Study of Mircera in Patients With Non-Hodgkin's Lymphoma and Anemia.
  Bruxelles; Research Site:
  
  
• Anemia: A Study of Mircera in Patients With Non-Hodgkin's Lymphoma and Anemia.
  Leuven; Research Site:
  
  
• Anemia: A Study of Mircera in Patients With Non-Hodgkin's Lymphoma and Anemia.
  Wilrijk; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Leuven; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Patients on Hemodialysis
  Mons; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Patients on Hemodialysis
  Roeselare; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Patients on Hemodialysis
  Verviers; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Patients on Hemodialysis
  Zottegem; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Aalst; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Bonheiden; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Brugge; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Bruxelles; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Charleroi; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Dendermonde; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Geel; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Gosselies; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Kortrijk; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Liege; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Merksem; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Mons; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Mont-Godinne; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Namur; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Oostende; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Roeselare; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Ronse; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Sint-Niklaas; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Tournai; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Verviers; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Vilvoorde; Research Site:
  
  
• Anemia: A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors
  Wilrijk; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Aalst; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Antwerpen; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Assebroek; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Ath; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Baudour; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Bonheiden; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Bruxelles; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Charleroi; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Dendermonde; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Edegem; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Genk; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Gent; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Hornu; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Huy; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Ieper; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  La Louvière; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Leuven; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Liege; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Liège; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Roeselare; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Sint Niklaas; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Tournai; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Turnhout; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
  Verviers; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
  Bruxelles; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
  Edegem; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
  Gent; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
  Hasselt; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.
  Aalst; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.
  Roeselare; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.
  Aalst; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.
  Roeselare; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera, Versus no ESA Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant.
  Edegem; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera, Versus no ESA Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant.
  Gent; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera, Versus no ESA Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant.
  Leuven; Research Site:
  
  
• Anemia: A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
  Brugge; Research Site:
  
  
• Anemia: A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
  Bruxelles; Research Site:
  
  
• Anemia: A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
  Edegem; Research Site:
  
  

Brazil

• Anemia: (ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy
  Sao Paulo; Research Site:
  
  
• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  Belo Horizonte; Research Site:
  
  
• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  Jaú; Research Site:
  
  
• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  Porto Alegre; Research Site:
  
  
• Anemia: A Study of Mircera for the Treatment of Anemia in Dialysis Patients
  Curitiba; Research Site:
  
  
• Anemia: A Study of Mircera for the Treatment of Anemia in Dialysis Patients
  Ribeirão Preto; Research Site:
  
  
• Anemia: A Study of Mircera for the Treatment of Anemia in Dialysis Patients
  Sao Paulo; Research Site:
  
  
• Anemia: A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
  Belem; Research Site:
  
  
• Anemia: A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
  Belo Horizonte; Research Site:
  
  
• Anemia: A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
  Blumenau; Research Site:
  
  
• Anemia: A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
  Botucatu; Research Site:
  
  
• Anemia: A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
  Curitiba; Research Site:
  
  
• Anemia: A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
  Rio De Janeiro; Research Site:
  
  
• Anemia: A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
  Sao Paulo; Research Site:
  
  
• Anemia: A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
  Taubaté; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Belo Horizonte; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Brasilia; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Campinas; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Campo Grande; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Cariacica; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Curitiba; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Fortaleza; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Jaboatão Dos Guararapes; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Joinville; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Juiz De Fora; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Londrina; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Natal; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Porto Alegre; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Ribeirão Preto; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Rio De Janeiro; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Salvador; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Sao Jose do Rio Preto; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Sao Luis; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Sao Paulo; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Sorocaba; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
  Curitiba; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
  Sao Paulo; Research Site:
  
  
• Anemia: LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Aracajú; Research Site:
  
  
• Anemia: LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Curitiba; Research Site:
  
  
• Anemia: LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Fortaleza; Research Site:
  
  
• Anemia: LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Sao Paulo; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Campinas; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Porto Alegre; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Santo Andre; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Sao Paulo; Research Site:
  
  

Bulgaria

• Anemia: A Study of NeoRecormon (Epoetin Beta) in Predialysis Patients With Renal Anemia
  Sofia; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Predialysis Patients With Renal Anemia
  Varna; Research Site:
  
  

Canada

• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
  Kingston, ON; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
  London, ON; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
  Mississauga, ON; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
  Montreal, QC; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
  Saskatoon, SK; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
  St John'S; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
  Toronto, ON; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
  Weston, ON; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Calgary, AB; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Edmonton, AB; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Halifax, NS; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Kamloops, BC; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Kitchener, ON; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Mississauga, ON; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Vancouver, BC; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Winnipeg, MB; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients
  Greenfield Park, QC; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients
  Montreal, QC; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients
  Ottawa, ON; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients
  Toronto, ON; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Calgary, AB; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Greenfield Park, QC; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Hamilton, ON; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Kitchener, ON; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Mississauga, ON; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Ottawa, ON; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Toronto, ON; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Trois-Rivieres, QC; Research Site:
  
  
• Anemia: A Study of Mircera for the Treatment of Anemia in Dialysis Patients
  Kingston, ON; Research Site:
  
  
• Anemia: A Study of Mircera for the Treatment of Anemia in Dialysis Patients
  London, ON; Research Site:
  
  
• Anemia: A Study of Mircera for the Treatment of Anemia in Dialysis Patients
  Montreal, QC; Research Site:
  
  
• Anemia: A Study of Mircera for the Treatment of Anemia in Dialysis Patients
  St John'S; Research Site:
  
  
• Anemia: A Study of Mircera for the Treatment of Anemia in Dialysis Patients
  Toronto, ON; Research Site:
  
  
• Anemia: A Study of Mircera for the Treatment of Anemia in Dialysis Patients
  Winnipeg, MB; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
  Edmonton, AB; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
  Montreal, QC; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.
  Montreal, QC; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.
  North Vancouver, BC; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.
  Ottawa, ON; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.
  Sainte-Foy, QC; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.
  Surrey, BC; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.
  Vancouver, BC; Research Site:
  
  
• Anemia: A Study of Mircera in Patients With Non-Hodgkin's Lymphoma and Anemia.
  Halifax, NS; Research Site:
  
  
• Anemia: A Study of Mircera in Patients With Non-Hodgkin's Lymphoma and Anemia.
  Ottawa, ON; Research Site:
  
  
• Anemia: A Study of Mircera in Patients With Non-Hodgkin's Lymphoma and Anemia.
  St John'S; Research Site:
  
  
• Anemia: A Study of Mircera in Patients With Non-Hodgkin's Lymphoma and Anemia.
  Toronto, ON; Research Site:
  
  
• Anemia: A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.
  Edmonton, AB; Research Site:
  
  
• Anemia: A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.
  Greenfield Park, QC; Research Site:
  
  
• Anemia: A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.
  Kingston, ON; Research Site:
  
  
• Anemia: A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.
  Kitchener, ON; Research Site:
  
  
• Anemia: A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.
  London, ON; Research Site:
  
  
• Anemia: A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.
  Mississauga, ON; Research Site:
  
  
• Anemia: A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.
  Montreal, QC; Research Site:
  
  
• Anemia: A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.
  Saskatoon, SK; Research Site:
  
  
• Anemia: A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.
  Scarborough, ON; Research Site:
  
  
• Anemia: A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.
  Toronto, ON; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Calgary, AB; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Edmonton, AB; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Kamloops, BC; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Kitchener, ON; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  London, ON; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Montreal, QC; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  New Westminster, BC; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Saskatoon, SK; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Scarborough, ON; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  St John'S; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Toronto, ON; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Vancouver, BC; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Winnipeg, MB; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.
  Calgary, AB; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.
  Kingston, ON; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.
  Mississauga, ON; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.
  Montreal, QC; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.
  St John'S; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.
  Toronto, ON; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.
  Weston, ON; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.
  Edmonton, AB; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.
  London, ON; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.
  Montreal, QC; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.
  Toronto, ON; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Edmonton, AB; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Halifax, NS; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Kingston, ON; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Mississauga, ON; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Moncton, NB; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Quebec City, QC; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Saskatoon, SK; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Toronto, ON; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Windsor, ON; Research Site:
  
  
• Lymphomas: A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.
  Greenfield Park, QC; Research Site:
  
  
• Lymphomas: A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.
  Quebec City, QC; Research Site:
  
  
• Multiple Myelomas: A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.
  Calgary, Alberta; Tom Baker Cancer Center
  
  
• Multiple Myelomas: A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.
  Edmonton, Alberta; Cross Cancer Institute
  
  

Chile

• Anemia: A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
  Santiago de Chile; Research Site:
  
  
• Anemia: LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Santiago; Research Site:
  
  

China

• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.
  Hong Kong; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
  Hong Kong; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) for Prevention and Treatment of Anemia in Patients With Solid Tumors Receiving Platinum-Based Chemotherapy Prone to Induce Anemia
  Beijing; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) for Prevention and Treatment of Anemia in Patients With Solid Tumors Receiving Platinum-Based Chemotherapy Prone to Induce Anemia
  Guangzhou; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) for Prevention and Treatment of Anemia in Patients With Solid Tumors Receiving Platinum-Based Chemotherapy Prone to Induce Anemia
  Shanghai; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) for Prevention and Treatment of Anemia in Patients With Solid Tumors Receiving Platinum-Based Chemotherapy Prone to Induce Anemia
  Shantou; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) for Prevention and Treatment of Anemia in Patients With Solid Tumors Receiving Platinum-Based Chemotherapy Prone to Induce Anemia
  Wuhan; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) for Treatment of Anemia in Patients With Hematologic Malignancies.
  Beijing; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) for Treatment of Anemia in Patients With Hematologic Malignancies.
  Shanghai; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) for Treatment of Anemia in Patients With Hematologic Malignancies.
  Tianjin; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) for Treatment of Anemia in Patients With Hematologic Malignancies.
  Wuhan; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) for Treatment of Anemia in Patients With Hematologic Malignancies.
  Xi'An; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.
  Hong Kong; Research Site:
  
  
• Anemia: A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
  Hong Kong; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Beijing; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Hong Kong; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Shanghai; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Tianjin; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Xi'An; Research Site:
  
  

Colombia

• Anemia: A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
  Bogota; Research Site:
  
  
• Anemia: A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
  Cali; Research Site:
  
  
• Anemia: LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Bogota; Research Site:
  
  
• Anemia: LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Bogotá; Research Site:
  
  

Costa Rica

• Anemia: A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
  San José; Research Site:
  
  

Czech Republic

• Anemia: (ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy
  Jihlava; Research Site:
  
  
• Anemia: (ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy
  Liberec; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Liberec; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Ostrava; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Plzen; Research Site:
  
  
• Anemia: A Study of Mircera for the Treatment of Anemia in Dialysis Patients
  Liberec; Research Site:
  
  
• Anemia: A Study of Mircera for the Treatment of Anemia in Dialysis Patients
  Praha; Research Site:
  
  
• Anemia: A Study of Mircera for the Treatment of Anemia in Dialysis Patients
  Usti Nad Labem; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Multiple Myeloma
  Praha; Research Site:
  
  
• Anemia: A Study of Mircera in Patients With Non-Hodgkin's Lymphoma and Anemia.
  Brno; Research Site:
  
  
• Anemia: A Study of Mircera in Patients With Non-Hodgkin's Lymphoma and Anemia.
  Olomouc; Research Site:
  
  
• Anemia: A Study of Mircera in Patients With Non-Hodgkin's Lymphoma and Anemia.
  Plzen; Research Site:
  
  
• Anemia: A Study of Mircera in Patients With Non-Hodgkin's Lymphoma and Anemia.
  Praha; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
  Brno; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
  Ostrava; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
  Plzen; Research Site:
  
  
• Anemia: A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
  Brno; Research Site:
  
  
• Anemia: A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
  Havirov; Research Site:
  
  
• Anemia: A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
  Olomouc; Research Site:
  
  
• Anemia: A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
  Ostrava; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Brno; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Cesky Krumlov; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Decin; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Havirov; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Hradec Kralove; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Jihlava; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Karlovy Vary; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Kolin Iii; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Liberec; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Novy Jicin; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Olomouc; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Ostrava; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Pisek; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Praha; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Strakonice; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Sumperk; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Tabor; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Teplice; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Trebic; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Usti Nad Labem; Research Site:
  
  
• Anemia: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
  Znojmo; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Brno; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Hradec Kralove; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Olomouc; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Plzen; Research Site:
  
  
• Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
  Praha; Research Site:
  
  

Denmark

• Anemia: (ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy
  København; Research Site:
  
  
• Anemia: (ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy
  Roskilde; Research Site:
  
  
• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  Århus; Research Site:
  
  
• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  Hillerød; Research Site:
  
  
• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  København; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Aalborg; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  København; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Odense; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Roskilde; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Aalborg; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Odense; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Roskilde; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Aalborg; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Hillerød; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Roskilde; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
  Aarhus; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
  Odense; Research Site:
  
  
• Anemia: A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
  Fredericia; Research Site:
  
  
• Anemia: A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
  Herlev; Research Site:
  
  
• Anemia: A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
  Holbaek; Research Site:
  
  
• Anemia: A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
  Roskilde; Research Site:
  
  
• Lymphomas: A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma
  Hillerød; Research Site:
  
  
• Lymphomas: A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma
  København; Research Site:
  
  

Ecuador

• Anemia: A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
  Quito; Research Site:
  
  
• Anemia: LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
  Quito; Research Site:
  
  

El Salvador

• Anemia: A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
  San Salvador; Research Site:
  
  

Estonia

• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
  Tallinn; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
  Tartu; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients With Chronic Kidney Disease.
  Tallinn; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients With Chronic Kidney Disease.
  Tartu; Research Site:
  
  

Finland

• Anemia: (ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy
  Jyvaeskylae; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Hus; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Pori; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Hus; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Tampere; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Tampere; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Turku; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
  Helsinki; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
  Hus; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
  Tampere; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
  Turku; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients With Chronic Kidney Disease.
  Hus; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients With Chronic Kidney Disease.
  Jyvaeskylae; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients With Chronic Kidney Disease.
  Kajaani; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients With Chronic Kidney Disease.
  Kotka; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients With Chronic Kidney Disease.
  Kuopio; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients With Chronic Kidney Disease.
  Porvoo; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients With Chronic Kidney Disease.
  Tampere; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients With Chronic Kidney Disease.
  Turku; Research Site:
  
  
• Anemia: A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
  Jyvaeskylae; Research Site:
  
  
• Anemia: A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
  Tampere; Research Site:
  
  

France

• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  Bayonne; Research Site:
  
  
• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  Brest; Research Site:
  
  
• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  Colmar; Research Site:
  
  
• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  Grenoble; Research Site:
  
  
• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  Limoges; Research Site:
  
  
• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  Mulhouse; Research Site:
  
  
• Anemia: (BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer
  Pierre Benite; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
  Aubervilliers; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
  Bordeaux; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
  La Tronche; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
  Paris; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
  Toulouse; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Aubervilliers; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Montpellier; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Nice; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Strasbourg; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Tarbes; Research Site:
  
  
• Anemia: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
  Toulouse; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients
  Chambery; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients
  Hyeres; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients
  Le Kremlin-Bicetre; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients
  Nantes; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients
  Paris; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients
  Rouen; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Amiens; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Bayonne; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Bordeaux; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Boulogne; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Cabestany; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Caen; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Chambery; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Colmar; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Hyeres; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  La Tronche; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Limoges; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Lyon; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Montpellier; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Nantes; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Nimes; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Paris; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Perpignan; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Poitiers; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Rouen; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Saint Ouen; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Saint-Germain-En-Laye; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Tarbes; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Thionville; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Toulouse; Research Site:
  
  
• Anemia: A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.
  Tours; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Auch; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Bordeaux; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Boulogne; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Cergy Pontoise; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Fleury-Merogis; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Herouville Saint Clair; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  La Tronche; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Lyon; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Montpellier; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Nimes; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Paris; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Reims; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Rennes; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Saint Brieuc; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Saint Herblain; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Saint Ouen; Research Site:
  
  
• Anemia: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
  Villeurbanne; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
  Colmar; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
  Paris; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
  Caen; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
  Dijon; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
  Lyon; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
  Paris; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
  Pessac; Research Site:
  
  
• Anemia: A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
  Saint Pierre; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Amiens; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Colmar; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Lyon; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Nantes; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Paris; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Perpignan; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Toulouse; Research Site:
  
  
• Anemia: A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Vandoeuvre-Les-Nancy; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Angers; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Besancon; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Caen; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Chambray-Lès-Tours; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Clichy; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Creteil; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Limoges; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Lyon; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Marseille; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Montpellier; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Nice; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Paris; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Pessac; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Rennes; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Saint Laurent Du Var; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Strasbourg; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Toulouse; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Tourcoing; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Vandoeuvre-Les-Nancy; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
  Villejuif; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Aix en Provence; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Ales; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Amiens; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Angers; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Angouleme; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Annecy; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Aulnay Sous Bois; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Avignon; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Bayonne; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Beauvais; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Blois; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Bobigny; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Bordeaux; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Bourg En Bresse; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Brest; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Brive; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Caen; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Chalon Sur Saone; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Chambery; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Clermont-Ferrand; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Colmar; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Creteil; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Dijon; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Grenoble; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Hyeres; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  La Garenne Colombes; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Le Chesnay; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Le Mans; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Lens; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Libourne; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Lille; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Limoges; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Lyon; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Marseille; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Martigues; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Metz; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Montelimar; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Montpellier; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Nantes; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Nice; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Nimes; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Orleans; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Paris; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Perpignan; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Pessac; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Pierre Benite; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Poitiers; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Quimper; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Rennes; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Rouen; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Saint Brieuc; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Saint Quentin; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Saint-Cloud; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Saint-Michel; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Saint-Priest-En-Jarez; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Strasbourg; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Toulon; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Toulouse; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Tours; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
  Vandoeuvre-Les-Nancy; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Patients on Hemodialysis
  Le Raincy; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Patients on Hemodialysis
  Lyon; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Patients on Hemodialysis
  Quimper; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Patients on Hemodialysis
  Reims; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Patients on Hemodialysis
  Saint Brieuc; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Patients on Hemodialysis
  St Priest En Jarez; Research Site:
  
  
• Anemia: A Study of NeoRecormon (Epoetin Beta) in the Treatment of Patients on Hemodialysis
  Strasbourg; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Aix en Provence; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Amiens; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Angers; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Annonay; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Avignon; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Bastia; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Beauvais; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Besancon; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Bois-Guillaume; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Bordeaux; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Boulogne Sur Mer; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Bourg En Bresse; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Bourges Cedex; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Bourgoin Jallieu; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Brest; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Caen; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Cergy Pontoise; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Chalon Sur Saone; Research Site:
  
  
• Anemia: A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis
  Chartres; Research Site: